<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pasireotide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pasireotide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pasireotide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="87800" href="/d/html/87800.html" rel="external">see "Pasireotide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16355589"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Signifor;</li>
<li>Signifor LAR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871540"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Signifor;</li>
<li>Signifor LAR</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15826667"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Somatostatin Analog</li></ul></div>
<div class="block doa drugH1Div" id="F16052571"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note: </b>In patients with diabetes mellitus, optimize antidiabetic therapy prior to initiating therapy. Correct hypokalemia and hypomagnesemia prior to initiating therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75f32ca4-cab6-48dd-9b89-a7bde464d597">Acromegaly</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acromegaly:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients who have persistent disease despite surgical resection (or in whom surgery is not appropriate), normal glucose tolerance, and inadequate response to first-line therapy (ACG [Melmed 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (Signifor LAR):</b> Initial: 40 mg once every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment:</i> May increase to 60 mg once every 4 weeks after ≥3 months if growth hormone and/or insulin-like growth factor-1 (IGF-1) levels have not normalized (maximum: 60 mg once every 4 weeks) (Colao 2014; Colao 2020; manufacturer’s labeling). If adverse reactions occur or IGF-1 level decreases below the lower limit of normal, decrease dosage (temporarily or permanently) in 20 mg decrements.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose: </i>If a dose is missed, dose may be given up to but no later than 2 weeks prior to the next dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b58b5af-6bad-40e2-96ee-0f42223a3654">Cushing disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cushing disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (Signifor):</b> Initial: 0.6 or 0.9 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment: </i>May increase dose in increments of 0.3 mg twice daily (eg, from 0.6 mg twice daily to 0.9 mg twice daily) every 3 months if 24-hour urinary free cortisol (UFC) levels have not normalized, up to 1.2 mg twice daily (Colao 2012; Petersenn 2017; manufacturer’s labeling). If adverse reactions occur, temporarily decrease dose by 0.3 mg twice daily. Recommended maintenance dosage range: 0.3 to 0.9 mg twice daily. <b>Note:</b> Maximum 24-hour UFC reductions are usually observed within 2 months of treatment (ES [Nieman 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (Signifor LAR):</b> Initial: 10 mg once every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment:</i> May increase dose after 4 months if 24-hour UFC levels have not normalized (maximum: 40 mg once every 4 weeks). If adverse reactions occur, may interrupt therapy (temporarily or permanently) or decrease to a previously tolerated dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose:</i> If a dose is missed, dose may be given up to but no later than 2 weeks prior to the next dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>If hypocortisolism occurs (including low serum cortisol levels and/or symptoms of adrenal insufficiency), consider temporarily reducing the dose or interrupting/discontinuing pasireotide therapy and initiating glucocorticoid replacement therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991542"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988651"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acromegaly:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Signifor LAR:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prior to initiation:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate hepatic impairment (Child-Pugh class B): Initial: 20 mg once every 4 weeks (maximum: 40 mg once every 4 weeks).</p>
<p style="text-indent:-2em;margin-left:8em;">Severe hepatic impairment (Child-Pugh class C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>During therapy: </i>Permanently discontinue therapy if signs/symptoms of clinically significant hepatic impairment occur.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Cushing disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Signifor:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prior to initiation:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate impairment (Child-Pugh class B): Initial: 0.3 mg twice daily (maximum: 0.6 mg twice daily)</p>
<p style="text-indent:-2em;margin-left:8em;">Severe impairment (Child-Pugh class C): Use not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>During therapy:</i></p>
<p style="text-indent:-2em;margin-left:8em;">If ALT increases &gt;3 times ULN or baseline value: Recheck ALT during recommended timeframe per recommendations in manufacturer's labeling for confirmation. If ALT level confirmed or increasing, interrupt therapy and investigate potential cause.</p>
<p style="text-indent:-2em;margin-left:8em;">If any liver test ≥5 times ULN (with a normal baseline) <b>OR</b> &gt;5 times the baseline value (with an abnormal baseline): Interrupt therapy and monitor liver tests more frequently per recommendations in manufacturer's labeling. If values return to normal or near normal, therapy may be reinitiated with extreme caution/monitoring only if another likely cause for hepatic effects is discovered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Signifor LAR:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prior to initiation:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate hepatic impairment (Child-Pugh class B): Initial: 10 mg once every 4 weeks (maximum: 20 mg once every 4 weeks).</p>
<p style="text-indent:-2em;margin-left:8em;">Severe hepatic impairment (Child-Pugh class C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>During therapy: </i>Permanently discontinue therapy if signs/symptoms of clinically significant hepatic impairment occur.</p></div>
<div class="block doe drugH1Div" id="F16052572"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F15898539"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (8% to 15%), peripheral edema (10% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (2% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (immediate release: 6% to 20%; long-acting release: 21% to 31%), hypercholesterolemia (6% to 11%), hyperglycemia (29% to 47%), hypoglycemia (3% to 15%), increased gamma-glutamyl transferase (9% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (5% to 12%), abdominal pain (8% to 25%), cholelithiasis (10% to 33%), decreased appetite (9% to 11%), diarrhea (immediate release: 58% to 59%; long-acting release: 16% to 39%), increased serum amylase (immediate release: 2%; long-acting release: 1% to 20%), increased serum lipase (immediate release: 6% to 9%; long-acting release: 1% to 30%), nausea (immediate release: 46% to 58%; long-acting release: 3% to 21%), upper abdominal pain (6% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Elevated glycosylated hemoglobin (5% to 12%), prolonged partial thromboplastin time (immediate release: 47%), prolonged prothrombin time (immediate release: 2% to 33%; long-acting release: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤14%), increased serum aspartate aminotransferase (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reactions (immediate release: 17% to 18%; long-acting release: 2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (immediate release: 6% to 11%), fatigue (10% to 27%), headache (immediate release: 28% to 29%; long-acting release: 3% to 19%), insomnia (immediate release: 4% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (immediate release: 6% to 16%), back pain (5% to 11%), increased creatine phosphokinase in blood specimen (long-acting release: 13%), myalgia (5% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (6% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (long-acting release: 6%), hypotension (6% to 8%), prolonged QT interval on ECG (1% to 6%), sinus bradycardia (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (immediate release: 7% to 9%), xeroderma (immediate release: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (2% to 7%), decreased cortisol, hyperuricemia (long-acting release: 7%), hypokalemia (immediate release: 5% to 7%), hypothyroidism (immediate release: 4%), impaired glucose tolerance/prediabetes, weight loss (long-acting release: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis (long-acting release: 1%), cholestasis (long-acting release: 4%), constipation (5% to 9%), flatulence (long-acting release: 5%), pancreatitis (long-acting release: ≤1%), vomiting (3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (2% to 10%), vertigo (immediate release: 5% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (6% to 10%), limb pain (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (long-acting release: 5%), upper respiratory tract infection (long-acting release: 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Endocrine &amp; metabolic: Diabetic ketoacidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ketoacidosis (includes patients without a history of diabetes)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis</p></div>
<div class="block coi drugH1Div" id="F16052362"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to pasireotide or any component of the formulation; moderate or severe hepatic impairment (Child-Pugh B or C); uncontrolled diabetes (HbA<sub>1c</sub> ≥8%) despite receiving anti-diabetic therapy; NYHA Class III to IV heart failure; cardiogenic shock; second- or third-degree atrioventricular (AV) block, sinoatrial block, sick sinus syndrome (unless patient has a functioning pacemaker); severe bradycardia; congenital long QT syndrome or baseline QTc interval ≥500 ms.</p></div>
<div class="block war drugH1Div" id="F16052363"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disorders: Bradycardia and QT prolongation have been observed with therapy. Use with caution in patients with preexisting cardiac disease, patients with risk factors for bradycardia (eg, high-grade heart block, history of significant bradycardia, receiving concomitant drugs known to cause bradycardia), and/or patients at risk for QT prolongation (eg, congenital long QT, recent myocardial infarction (MI), heart failure, unstable angina, hypokalemia, hypomagnesemia, receiving concomitant drugs known to cause QT prolongation). Correct hypokalemia and/or hypomagnesemia prior to therapy and monitor during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholelithiasis: Cholelithiasis and complications of cholelithiasis (eg, cholecystitis, cholangitis, pancreatitis) requiring cholecystectomy have been reported; monitor periodically for cholelithiasis; discontinue and treat appropriately if suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Increased liver enzymes have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia/diabetes/ketoacidosis: Inhibition of insulin and glucagon secretion may affect glucose regulation, leading to hyperglycemia (sometimes severe). Cases of ketoacidosis have been reported in patients with or without a history of diabetes; patients with predisposing factors, including acute illness, infection, pancreatic disorders (eg, pancreatic malignancy, pancreatic surgery), and alcohol abuse may be at greater risk. Exacerbation of glycemia occurred in the majority of patients during the initial months of therapy, including patients with normal glucose levels at baseline; diabetes and prediabetes has also been observed. Patients with poor baseline glycemic control are at higher risk of developing severe hyperglycemia. If hyperglycemia occurs, initiation or dosage adjustment of antidiabetic therapy is recommended; if uncontrolled hyperglycemia persists despite antidiabetic therapy, consider dosage reduction or discontinuation of pasireotide. Following discontinuation of pasireotide, continued monitoring of blood glucose may be required if hypoglycemia is a risk. Assess patients presenting with signs and symptoms consistent with severe metabolic acidosis for ketoacidosis; discontinue pasireotide and promptly treat patients if ketoacidosis is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocortisolism: Suppression of the adrenocorticotropic hormone from therapy may lead to hypocortisolism in Cushing disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: Decreases (slight) in thyroid function have been observed during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pituitary hormone deficiency (anterior): May cause inhibition of anterior pituitary hormones. Patients who have undergone transsphenoidal surgery and pituitary irradiation are at an increased risk for deficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Exacerbation of glycemia commonly occurs with pasireotide use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p></div>
<div class="block foc drugH1Div" id="F16355590"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as diaspartate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Signifor: 0.3 mg/mL (1 mL); 0.6 mg/mL (1 mL); 0.9 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular, as pamoate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Signifor LAR: 10 mg (1 ea); 30 mg (1 ea); 20 mg (1 ea); 40 mg (1 ea); 60 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F20452830"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570464"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Signifor Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/mL (per mL): $366.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.6 mg/mL (per mL): $366.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.9 mg/mL (per mL): $366.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (Signifor LAR Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $20,896.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $20,896.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $20,896.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $20,896.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $20,896.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871541"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as diaspartate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Signifor: 0.3 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular, as pamoate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Signifor LAR: 10 mg (1 ea); 30 mg (1 ea); 20 mg (1 ea); 40 mg (1 ea); 60 mg (1 ea)</p></div>
<div class="block accres drugH1Div" id="F23286622"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">In Canada, patients prescribed Signifor must be enrolled in the Access Program for Signifor (Novartis Canada).</p></div>
<div class="block adm drugH1Div" id="F16052574"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Signifor LAR: Administer only by IM injection into the left or right gluteus immediately after reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Signifor: Administer only by SUBQ injection into the top of the thigh or abdomen (excluding the navel and waistline). Do not inject into inflamed or irritated skin. Alternate the injection site.</p></div>
<div class="block hazard drugH1Div" id="F49132757"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">For IM or SUBQ preparation, NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator). Double gloving and a protective gown are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block meg drugH1Div" id="F15840328"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Signifor: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F200677s003lbl.pdf%23page%3D18&amp;token=U56BP0StyCtmP%2Bg8VrG641SL8UsZPIYwreEyyOq7JbmSbNqnqTQVajJDnPokwNqc37MqxAe9PCGK3y%2FfYkDeDSnp1iAbOjKZWSeIDBIOhOuA4GtOCan0GhbaF0fF2pCR&amp;TOPIC_ID=87457" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/200677s003lbl.pdf#page=18</a></p>
<p style="text-indent:-2em;margin-left:4em;">Signifor LAR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F203255s004lbl.pdf%23page%3D27&amp;token=J%2F59oNk1H0x%2FHGiiyZphJpEaak2jpQ1fPA%2BeymMCbdJKx%2BsichD3qh0%2Bthm%2F8fZnlc1YYcqSiHD%2BTtyCDYZXlR7NH5vjsl6PVLz6r6N3rzQVnAf9K20FAkMmeKV6QJ7o&amp;TOPIC_ID=87457" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203255s004lbl.pdf#page=27</a></p></div>
<div class="block use drugH1Div" id="F15826669"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acromegaly</b>
<b>(Signifor LAR):</b> Treatment of acromegaly in patients who have had an inadequate response to surgery and/or for whom surgery is not an option.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cushing disease (Signifor and Signifor LAR): </b>Treatment of Cushing disease in patients for whom pituitary surgery is not an option or has not been curative</p></div>
<div class="block mst drugH1Div" id="F16052357"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pasireotide may be confused with lanreotide, octreotide</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F16061149"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16061147"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: Somatostatin Analogs may decrease serum concentrations of the active metabolite(s) of Codeine. Specifically, the concentrations of the active metabolite morphine may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copper Cu 64 Dotatate: Somatostatin Analogs may diminish the diagnostic effect of Copper Cu 64 Dotatate.  Management: Imaging with copper Cu 64 dotatate positron emission tomography (PET) should be performed just prior to dosing with somatostatin analogs. If on somatostatin analogs, stop long-acting agents 28 days before, and short-acting agents 2 days before, imaging.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Somatostatin Analogs may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Somatostatin Analogs may diminish the diagnostic effect of Gallium Ga 68 Dotatate. Specifically, a false negative PET scan may occur if Gallium GA 68 Dotatate is used during treatment with somatostatin analogs.  Management: It is recommended to image with gallium Ga 68 dotatate positron emission tomography (PET) just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatoc: Somatostatin Analogs may diminish the diagnostic effect of Gallium Ga 68 Dotatoc.  Management: Imaging with gallium Ga 68 dotatoc positron emission tomography (PET) should be performed just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatoc.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Somatostatin Analogs may diminish the therapeutic effect of Lutetium Lu 177 Dotatate. Specifically, the therapeutic effect of Lutetium Lu 177 Dotatate may be diminished if the timing of Somatostatin Analog administration is not carried out as recommended.  Management: Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to lutetium Lu 177 dotatate dose. Administer short and long-acting octreotide during treatment as recommended. See full interaction monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Somatostatin Analogs may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49309073"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Fertility may be improved with treatment in patients who may become pregnant following normalization of serum cortisol in patients with Cushing disease, and normalization of insulin-like growth factor 1 and growth hormone in patients with acromegaly. Pasireotide may be used for patients with acromegaly who are trying to conceive; discontinue once pregnancy is confirmed (ESE [Luger 2021]). The Endocrine Society acromegaly guidelines recommend patients who may become pregnant use adequate contraception during treatment, and suggest discontinuing long-acting formulations of somatostatin analogs approximately 2 months prior to a planned pregnancy; short-acting octreotide may be used until conception if needed for the treatment of acromegaly (ES [Katznelson 2014]).</p></div>
<div class="block pri drugH1Div" id="F16052359"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of pasireotide is insufficient to recommend its use for the treatment of acromegaly during pregnancy (ESE [Luger 2021]). If treatment for acromegaly is required during pregnancy for worsening symptoms (eg, headaches or evidence of worsening tumor), alternative agents are recommended. Monitoring of insulin-like growth factor 1 (IGF-1) and/or growth hormone (GH) is not recommended during pregnancy, as an active placental GH variant present in maternal blood limits the usefulness of the results (ES [Katznelson 2014]; ESE [Luger 2021]). Information related to the use of pasireotide is also insufficient to recommend its use for the treatment of Cushing syndrome in pregnant patients (ESE [Luger 2021]).</p></div>
<div class="block brc drugH1Div" id="F16052361"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pasireotide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F16052583"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">ECG at baseline (also consider continued monitoring during treatment; in patients receiving Signifor LAR who are at high risk of QT prolongation, repeat 21 days after injection); serum potassium and magnesium (prior to and periodically during therapy); pituitary function (eg, thyroid-stimulating hormone, free thyroxine, growth hormone [GH], insulin-like growth factor-1 [IGF-1], gonadal function; baseline then periodically); adrenal function (including signs/symptoms of adrenal insufficiency; prior to and periodically during therapy); heart rate (patients with cardiac disease and/or risk factor for bradycardia); cholelithiasis (periodically during therapy; in patients receiving Signifor, perform gall bladder ultrasonography at baseline and every 6 to 12 months during therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">Glycemic parameters: FBG and HbA<sub>1c</sub> prior to initiation; blood glucose weekly for the first 2 to 3 months and periodically thereafter as appropriate; monitor blood glucose weekly following dose increases for several weeks (eg, for 2 to 4 weeks in patients receiving Signifor, and for 4 to 6 weeks in patients receiving Signifor LAR). If glucose tolerance is consistently normal after 3 months of monitoring, may consider reduced monitoring (eg, HbA1c every 3 to 6 months [Coopmans 2019]). Following discontinuation of pasireotide, continued monitoring of blood glucose may be required if hypoglycemia is a risk.</p>
<p style="text-indent:-2em;margin-left:4em;">Liver function tests:</p>
<p style="text-indent:-2em;margin-left:6em;">Signifor LAR: Prior to initiation, 2 to 3 weeks after initiation, then monthly for 3 months and as clinically indicated; during therapy, discontinue if clinically significant liver impairment develops and monitor liver function until resolution.</p>
<p style="text-indent:-2em;margin-left:6em;">Signifor: Prior to initiation, 1 to 2 weeks after initiation, then monthly for 3 months, then every 6 months thereafter; more frequent testing may be necessary:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If ALT <b>normal at baseline</b> and ALT increases 3 to 5 times ULN on therapy:</i> Repeat ALT within 1 week</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If ALT <b>normal at baseline</b> and ALT increases &gt;5 times ULN on therapy:</i> Repeat ALT within 48 hours</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If ALT <b>abnormal at baseline </b>and ALT increases 3 to 5 times baseline values on therapy:</i> Repeat ALT within 1 week</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>If ALT <b>abnormal at baseline </b> and ALT increases &gt;5 times ULN on therapy:</i> Repeat ALT &lt;1 week</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> ALT levels should be done in a laboratory capable of same-day results; if ALT levels are confirmed or rising, interrupt therapy and investigate cause.</p>
<p style="text-indent:-2em;margin-left:8em;">During therapy, if any liver test ≥5 times ULN (with a normal baseline) <b>OR</b> &gt;5 times the baseline value (with an abnormal baseline), interrupt therapy and monitor ALT, AST, alkaline phosphatase, and total bilirubin weekly or more frequently. If values return to normal or near normal, therapy may be reinitiated with extreme caution/monitoring only if another likely cause for hepatic effects discovered.</p>
<p style="text-indent:-2em;margin-left:2em;">Acromegaly: Serum GH and IGF-1 levels at 3 months (prior to dosage adjustment) and as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Cushing disease: Urinary free cortisol (24-hour) at 4 months (prior to dosage adjustment) and as clinically indicated.</p></div>
<div class="block rer drugH1Div" id="F51990690"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;">
<b>Acromegaly: </b>Age-normalized serum insulin-like growth factor 1 (IGF-1) and a random growth hormone (GH) &lt;1 mcg/L correlate with control of acromegaly; consider targeting postoperative GH level &lt;0.4 mcg/L if ultra-sensitive GH assay is available; use of the same IGF-1 and GH assay in the same patient throughout management is suggested (ACG [Melmed 2018]; ES [Katznelson 2014]).</p>
<p style="text-indent:0em;display:inline">
<b>Cushing disease: </b>Morning serum cortisol level &lt;5 mcg/dL (&lt;138 nmol/L) or urinary free cortisol level &lt;10 to 20 mcg/day (&lt;28 to 56 nmol/day) (ES [Nieman 2015]).</p></div>
<div class="block pha drugH1Div" id="F16052547"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pasireotide is a cyclohexapeptide somatostatin analog, which is a peptide inhibitor of multiple endocrine, neuroendocrine, and exocrine mechanisms. In patients with Cushing disease, pasireotide binds to somatostatin receptor (sst<sub>1-5</sub>), with high affinity for the sst<sub>1</sub>, sst<sub>2</sub>, sst<sub>3</sub> subtypes, and highest affinity for the sst<sub>5</sub> subtype, resulting in inhibition of ACTH secretion which leads to decreased cortisol secretion. In patients with acromegaly, pasireotide binds to sst<sub>2</sub> and sst<sub>5</sub>, resulting in decreased GH and IGF-1.</p></div>
<div class="block phk drugH1Div" id="F16052549"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: &gt;100 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 88%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily eliminated as unchanged drug hepatically (via biliary excretion)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Subcutaneous: ~12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Subcutaneous: 0.25 to 0.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~40% to 56%, primarily as unchanged drug); urine (~6% to 10%, primarily as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51192060"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC<sub>inf</sub> was increased by 12%, 56%, and 42% and C<sub>max</sub> was increased by 3%, 46%, and 33%, respectively, in mild, moderate, and severe hepatic impairment (Child-Pugh class A, B, and C).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059518"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Upelior</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Signifor lar</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Signifor lar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Signifor lar</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Signifor | Signifor lar</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Signifor</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Signifor lar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32217809">
<a name="32217809"></a>Colao A, Bronstein MD, Brue T, et al. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. <i>Eur J Endocrinol</i>. 2020;182(6):583. doi:10.1530/EJE-19-0762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/32217809/pubmed" id="32217809" target="_blank">32217809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24423324">
<a name="24423324"></a>Colao A, Bronstein MD, Freda P, et al; Pasireotide C2305 Study Group. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. <i>J Clin Endocrinol Metab</i>. 2014;99(3):791-799. doi:10.1210/jc.2013-2480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/24423324/pubmed" id="24423324" target="_blank">24423324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397653">
<a name="22397653"></a>Colao A, Petersenn S, Newell-Price J, et al; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. <i>N Engl J Med</i>. 2012;366(10):914-924. doi:10.1056/NEJMoa1105743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/22397653/pubmed" id="22397653" target="_blank">22397653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30608534">
<a name="30608534"></a>Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers SJCMM. How to position pasireotide LAR treatment in acromegaly. <i>J Clin Endocrinol Metab</i>. 2019;104(6):1978-1988. doi:10.1210/jc.2018-01979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/30608534/pubmed" id="30608534" target="_blank">30608534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25356808">
<a name="25356808"></a>Katznelson L, Laws ER Jr, Melmed S, et al; Endocrine Society (ES). Acromegaly: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(11):3933-3951. doi: 10.1210/jc.2014-2700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/25356808/pubmed" id="25356808" target="_blank">25356808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34425558">
<a name="34425558"></a>Luger A, Broersen LHA, Biermasz NR, et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. <i>Eur J Endocrinol</i>. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/34425558/pubmed" id="34425558" target="_blank">34425558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30050156">
<a name="30050156"></a>Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. <i>Nat Rev Endocrinol</i>. 2018;14(9):552-561. doi:10.1038/s41574-018-0058-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/30050156/pubmed" id="30050156" target="_blank">30050156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26222757">
<a name="26222757"></a>Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/26222757/pubmed" id="26222757" target="_blank">26222757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28597198">
<a name="28597198"></a>Petersenn S, Salgado LR, Schopohl J, et al. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a phase III trial. <i>Endocrine</i>. 2017;57(1):156-165. doi:10.1007/s12020-017-1316-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/28597198/pubmed" id="28597198" target="_blank">28597198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20410233">
<a name="20410233"></a>Petersenn S, Schopohl J, Barkan A, et al, “Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients With Acromegaly: A Randomized, Multicenter, Phase II Trial,” <i>J Clin Endocrinol Metab</i>, 2010, 95(6):2781-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/20410233/pubmed" id="20410233" target="_blank">20410233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22713526">
<a name="22713526"></a>Shenouda M, Maldonado M, Wang Y, et al, “An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers: Safety, Tolerability, and Effects on Glucose, Insulin, and Glucagon Levels,” <i>Am J of Ther</i>, 2012 [epub ahead of print].<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pasireotide-drug-information/abstract-text/22713526/pubmed" id="22713526" target="_blank">22713526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Signifor (pasireotide) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; March 2020.</div>
</li>
<li>
<div class="reference">
                  Signifor (pasireotide) [product monograph]. Toronto, Ontario, Canada: Recordati Rare Diseases Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Signifor LAR (pasireotide) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  Signifor LAR (pasireotide) [product monograph]. Toronto, Ontario, Canada: Recordati Rare Diseases Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 87457 Version 217.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
